Patents by Inventor Yon Hui Kim

Yon Hui Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Maker for diagnosing HER2 inhibitor resistant cancer, diagnostic kit comprising same, and method for diagnosing HER2 inhibitor resistant cancer
    Patent number: 10190170
    Abstract: The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: January 29, 2019
    Assignee: NATIONAL CANCER CENTER
    Inventors: Hae Ryung Chang, Youme Gim, Hae Rim Jung, Seung Yoon Nam, Jung sil Ro, Yon Hui Kim
  • HNF4-? antagonist and use thereof
    Patent number: 9795586
    Abstract: Provided is a hepatocyte nuclear factor 4 alpha (HNF4-?) antagonist and a use thereof. The HNF4-? antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-?, thereby inhibiting the activity of HNF4-?. The HNF4-? antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-? antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-? antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-?.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: October 24, 2017
    Assignee: NATIONAL CANCER CENTER
    Inventors: Yon Hui Kim, Seung Yoon Nam, Hee Seo Park, Hae Ryung Chang, Hae Rim Jung
  • HNF4-alpha ANTAGONIST AND USE THEREOF
    Publication number: 20170189371
    Abstract: Provided is a hepatocyte nuclear factor 4 alpha (HNF4-?) antagonist and a use thereof. The HNF4-? antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-?, thereby inhibiting the activity of HNF4-?. The HNF4-? antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-? antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-? antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-?.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Inventors: Yon Hui KIM, Seung Yoon NAM, Hee Seo PARK, Hae Ryung CHANG, Hae Rim JUNG
  • HNF4-alpha ANTAGONIST AND USE THEREOF
    Publication number: 20160193238
    Abstract: Provided is a hepatocyte nuclear factor 4 alpha (HNF4-?) antagonist and a use thereof. The HNF4-? antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-?, thereby inhibiting the activity of HNF4-?. The HNF4-? antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-? antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-? antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-?.
    Type: Application
    Filed: January 5, 2016
    Publication date: July 7, 2016
    Inventors: Yon Hui Kim, Seung Yoon Nam, Hee Seo Park, Hae Ryung Chang, Hae Rim Jung
  • MAKER FOR DIAGNOSING HER2 INHIBITOR RESISTANT CANCER, DIAGNOSTIC KIT COMPRISING SAME, AND METHOD FOR DIAGNOSING HER2 INHIBITOR RESISTANT CANCER
    Publication number: 20150368722
    Abstract: The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.
    Type: Application
    Filed: May 29, 2015
    Publication date: December 24, 2015
    Inventors: Hae Ryung Chang, Youme Gim, Hae Rim Jung, Seung Yoon Nam, Jung sil Ro, Yon Hui Kim